{"id":2951,"date":"2026-08-26T10:15:34","date_gmt":"2026-08-26T09:15:34","guid":{"rendered":"https:\/\/officialcorepeptides.brandloom.net\/fr\/?post_type=product&p=2951"},"modified":"2026-08-26T10:15:35","modified_gmt":"2026-08-26T09:15:35","slug":"buy-sermorelin-in-switzerland","status":"publish","type":"product","link":"https:\/\/officialcorepeptides.ch\/fr\/product\/buy-sermorelin-in-switzerland\/","title":{"rendered":"Sermorelin (5MG)"},"content":{"rendered":"

What Is Sermorelin?<\/h2>\n

Sermorelin is a synthetic 29-amino acid peptide with the sequence Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH2. It corresponds to the N-terminal 1-29 fragment of the 44-amino acid endogenous growth hormone-releasing hormone (GHRH). Researchers have established that this 29-residue fragment retains the full biological activity of the native hormone, as the first 29 residues contain the complete receptor-binding domain. For those looking to buy Sermorelin in Switzerland<\/strong>, Core Peptides offers high-quality research-grade material for laboratory applications.<\/p>\n

Researchers classify Sermorelin as a synthetic peptide analog within the category of pharmaceutical-grade research materials. Its molecular formula is C149H246N44O42S with a molecular weight of approximately 3,357.9 g\/mol, and it is identified by CAS number 86168-78-7. The peptide features C-terminal amidation, which contributes to its biological stability.<\/p>\n

Sermorelin Research Overview<\/h2>\n

Sermorelin has attracted sustained scientific interest as a well-characterized GHRH analog with an extensive research history spanning over four decades in growth hormone physiology. Unlike direct administration of exogenous growth hormone, Sermorelin stimulates the pituitary gland to produce and secrete endogenous GH. This mode of action preserves the natural pulsatile release of GH and remains subject to the body’s own negative feedback mechanisms, primarily through somatostatin, which mitigates the risk of overdose.<\/p>\n

Research interest in Sermorelin centers on its ability to bind the GHRH receptor (GHRH-R) on somatotroph cells of the anterior pituitary, activating intracellular signaling cascades that lead to growth hormone synthesis and secretion. Consequently, Sermorelin has generated significant interest as a research tool for investigating GHRH receptor pharmacology, somatotroph function, the hypothalamic-pituitary-somatotroph axis, and growth hormone physiology.<\/p>\n

When researchers choose to buy Sermorelin in Switzerland<\/strong> for laboratory studies, they gain access to a compound that may help elucidate mechanisms of GHRH receptor signaling, cAMP-mediated transcription, and growth hormone regulation at the molecular level.<\/p>\n

How Does Sermorelin Work?<\/h2>\n

Sermorelin exerts its biological effects through binding to the growth hormone-releasing hormone receptor (GHRH-R), a member of the G-protein coupled receptor (GPCR) superfamily predominantly expressed on the surface of somatotroph cells in the anterior pituitary gland. The peptide’s mechanism involves several well-characterized steps.<\/p>\n

GHRH Receptor Binding and Activation<\/h3>\n

Sermorelin, as a GHRH analog, competitively binds to the GHRH-R. This binding induces a conformational change in the receptor, which in turn activates its associated heterotrimeric G-protein. The G-protein primarily associated with the GHRH-R is the stimulatory G-protein, Gs.<\/p>\n

cAMP\/PKA Signaling Pathway<\/h3>\n

Upon activation of the Gs protein, a cascade of intracellular signaling events is initiated. The primary and most well-elucidated pathway is the cyclic adenosine monophosphate (cAMP) \/ Protein Kinase A (PKA) pathway. The activation of the Gs alpha subunit by the sermorelin-bound GHRH-R leads to the stimulation of adenylyl cyclase. This enzyme catalyzes the conversion of ATP to cyclic AMP (cAMP). The subsequent increase in intracellular cAMP levels activates Protein Kinase A (PKA).<\/p>\n

Activated PKA then phosphorylates various downstream targets, including the transcription factor cAMP response element-binding protein (CREB). Phosphorylated CREB translocates to the nucleus and binds to cAMP response elements (CRE) in the promoter region of the growth hormone gene, thereby enhancing its transcription. This leads to an increased synthesis of GH mRNA and, consequently, growth hormone.<\/p>\n

The PLC\/IP3\/DAG Signaling Pathway<\/h3>\n

In addition to the primary cAMP\/PKA pathway, sermorelin-mediated activation of the GHRH-R can also stimulate Phospholipase C (PLC) through the \u03b2\u03b3-subunits of the G-protein. PLC activation leads to the hydrolysis of phosphatidylinositol 4,5-bisphosphate (PIP2) into two second messengers: inositol trisphosphate (IP3) and diacylglycerol (DAG). This secondary pathway contributes to the overall physiological effect.<\/p>\n

Researchers who buy Sermorelin in Switzerland<\/strong> for research purposes can investigate these mechanisms across diverse experimental models of GHRH receptor signaling, somatotroph function, and growth hormone physiology.<\/p>\n

Why Is Sermorelin Studied?<\/h2>\n

Researchers study Sermorelin primarily for its potential relevance to GHRH receptor pharmacology, somatotroph function, and growth hormone physiology. The peptide’s ability to selectively activate the GHRH receptor and stimulate endogenous GH secretion makes it a valuable tool for understanding the molecular basis of the hypothalamic-pituitary-somatotroph axis.<\/p>\n

Researchers have studied Sermorelin as a diagnostic agent for growth hormone deficiency. Unlike direct GH injection, Sermorelin works by signaling the pituitary gland to release endogenous growth hormone. Clinical evidence supports its use as a diagnostic agent for GH assessment, and researchers have explored it in the context of adult GH deficiency and age-related GH decline.<\/p>\n

Moreover, researchers study Sermorelin in the context of the natural feedback architecture of the hypothalamic-pituitary-somatotroph axis. In research models, Sermorelin serves as a tool that preserves sensitivity to somatostatin-mediated inhibition, offering a more physiologically relevant approach to investigating growth hormone regulation compared to direct GH administration.<\/p>\n

Researchers who buy Sermorelin in Switzerland<\/strong> from Core Peptides can incorporate this peptide into their studies on GHRH receptor signaling, somatotroph function, growth hormone physiology, and endocrine research.<\/p>\n

Sermorelin Research Areas<\/h2>\n\n\n\n\n\n\n\n\n\n\n\n\n
Research Area<\/th>\nDescription<\/th>\n<\/tr>\n<\/thead>\n
GHRH Receptor Pharmacology<\/strong><\/td>\nInvestigating Sermorelin’s binding affinity and selectivity for the GHRH receptor<\/td>\n<\/tr>\n
Somatotroph Function<\/strong><\/td>\nStudying Sermorelin’s effects on GH synthesis and secretion in pituitary cells<\/td>\n<\/tr>\n
cAMP\/PKA Signaling<\/strong><\/td>\nExamining Sermorelin’s activation of adenylyl cyclase and downstream CREB-mediated transcription<\/td>\n<\/tr>\n
Growth Hormone Physiology<\/strong><\/td>\nExploring Sermorelin’s role in pulsatile GH secretion and the hypothalamic-pituitary-somatotroph axis<\/td>\n<\/tr>\n
Endocrine Research<\/strong><\/td>\nInvestigating Sermorelin’s effects on the GH\/IGF-1 axis and metabolic regulation<\/td>\n<\/tr>\n
Diagnostic Agent Studies<\/strong><\/td>\nPreclinical research into Sermorelin’s utility in GH deficiency assessment<\/td>\n<\/tr>\n
Receptor Binding Studies<\/strong><\/td>\nInvestigating the molecular basis of GHRH receptor-ligand interactions<\/td>\n<\/tr>\n
Structure-Activity Relationships<\/strong><\/td>\nExamining the pharmacophore requirements for GHRH receptor activation<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Scientific Research on Sermorelin<\/h2>\n

Researchers have conducted extensive scientific studies on Sermorelin in both in vitro and in vivo settings, deriving evidence from cell cultures, preclinical models, and clinical research. The peptide has an extensive research history spanning over four decades in growth hormone physiology.<\/p>\n

In Vitro Evidence<\/h3>\n

In vitro studies using pituitary cell cultures have demonstrated that Sermorelin binds to the GHRH receptor on somatotroph cells, activating Gs-protein-coupled adenylyl cyclase and increasing intracellular cAMP concentrations. This signaling cascade plays a well-established role in the synthesis and secretion of growth hormone (GH) in a pulsatile manner.<\/p>\n

Furthermore, research has shown that Sermorelin, as the N-terminal 29-amino acid fragment of GHRH, retains the full biological activity of the native 44-amino acid hormone. The potency of Sermorelin equals that of the naturally occurring GHRH(1-40) and GHRH(1-44) isoforms.<\/p>\n

Preclinical Studies<\/h3>\n

In animal models, researchers have investigated Sermorelin’s effects on growth hormone secretion and pituitary function. For instance, studies have examined the GH response to GHRH and Sermorelin in various experimental settings. Researchers have studied the peptide in contexts including growth hormone deficiency, age-related GH decline, and endocrine research.<\/p>\n

Additionally, research has explored Sermorelin’s metabolic stability and degradation profile. Studies have demonstrated that Sermorelin and its metabolite rapidly degrade at temperatures above 4\u00b0C and pH values below 7, highlighting the importance of proper storage and handling in laboratory settings.<\/p>\n

Human Research<\/h3>\n

Researchers have studied Sermorelin in human clinical research, and it has been licensed as a diagnostic test for growth hormone secretion. It has also been used in the treatment of growth hormone deficiency in children. However, products containing Sermorelin were withdrawn from the United States market by the manufacturer in November 2002.<\/p>\n

Researchers have also investigated the peptide in the context of adult-onset growth hormone insufficiency and have explored it for age-related GH decline. Studies on treatment with GH secretagogues or GHRH for periods ranging from 20 weeks to 12 months have not reported significant side effects.<\/p>\n

Nevertheless, researchers should note that Sermorelin is supplied for laboratory research purposes only. Scientists who buy Sermorelin in Switzerland<\/strong> should remain aware of these evidence considerations.<\/p>\n

Sermorelin Compared With Related Peptides<\/h2>\n\n\n\n\n\n\n\n\n\n
Peptide<\/th>\nRelationship to Sermorelin<\/th>\nKey Differences<\/th>\n<\/tr>\n<\/thead>\n
Native GHRH (1-44)<\/strong><\/td>\nParent compound; Sermorelin is a truncated analog<\/td>\nNative GHRH has 44 amino acids; Sermorelin has 29 amino acids (N-terminal fragment) with equal biological potency<\/td>\n<\/tr>\n
Tesamorelin<\/strong><\/td>\nBoth are GHRH analogs<\/td>\nTesamorelin has C-terminal lipophilic modification for extended half-life; Sermorelin has shorter duration<\/td>\n<\/tr>\n
CJC-1295<\/strong><\/td>\nBoth are GHRH analogs<\/td>\nCJC-1295 has drug affinity complex for extended half-life; Sermorelin is the native 29-amino acid fragment<\/td>\n<\/tr>\n
Ipamorelin<\/strong><\/td>\nBoth studied for growth hormone research<\/td>\nIpamorelin is a GHRP (ghrelin receptor agonist); Sermorelin is a GHRH receptor agonist (different mechanism)<\/td>\n<\/tr>\n
Growth Hormone (GH)<\/strong><\/td>\nSermorelin stimulates endogenous GH secretion<\/td>\nGH is direct exogenous administration; Sermorelin stimulates natural pulsatile GH release<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Research Applications<\/h2>\n

Researchers utilize Sermorelin in a variety of laboratory research applications, primarily in the fields of endocrinology, receptor pharmacology, and growth hormone physiology. Key research applications include:<\/p>\n